JC
XLRN

Jetstream Capital’s Acceleron Pharma XLRN Stock Holding History

Jetstream Capital’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-40,000
Closed -$1.21M – 51
2014
Q3 		$1.21M Buy
+40,000
New +$1.13M 0.02% 28

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jetstream Capital's XLRN Position: Q4 2014 in Review

Jetstream Capital sold out of Acceleron Pharma (XLRN) in Q4 2014, closing a stake of 40,000 shares — an estimated $1.21M sold.

Jetstream Capital first reported a position in XLRN in Q3 2014 and held it in 1 quarter. The position peaked at $1.21M in Q3 2014. 110 funds tracked by Wall St. Rank hold XLRN as of Q4 2014.

  • Jetstream Capital reported no remaining Acceleron Pharma position as of Q4 2014 after selling out during the quarter.
  • Jetstream Capital sold 40,000 Acceleron Pharma shares in Q4 2014, an estimated $1.21M.
  • Jetstream Capital first reported a position in Acceleron Pharma in Q3 2014 and held it in 1 quarter.
  • Jetstream Capital's Acceleron Pharma position peaked at $1.21M in Q3 2014.
  • 110 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2014.

Based on Jetstream Capital's 13F filing for Q4 2014, filed 17 Feb 2015.